An illustration of DNA double helices is shown next to UCSF neuro-oncologist Jennifer Clarke, MD, MPH.

A phase 1 clinical trial led by @ucsfhealth.bsky.social neuro-oncologist Jennifer Clarke, MD, MPH, shows that a personalized treatment regimen with multiple targeted therapies is a feasible approach for recurrent #glioblastoma: braintumorcenter.ucsf.edu/news/precisi... @ucsfcancer.bsky.social

Neuro-Oncology: The Podcast: Hot Topics: How longitudinal profiling of glioma informs therapy development Dr. Dave Rogawski interviews Dr. David Solomon on his research that sheds light on how key genomic alterations in high-grade glioma evolve over time and how these insights might inform therapeutic dev...

It was a great pleasure to discuss our recent longitudinal genomic profiling studies of both IDH-wildtype glioblastomas and IDH-mutant astrocytomas together with Dr. Dave Rogawski of @stanfordbraintumor.bsky.social for the Neuro-Oncology podcast series: soc-neuro-onc.libsyn.com/hot-topics-h...

Full results of this first-in-class phase 1 clinical trial for recurrent glioblastoma now available online first ahead of print in Clinical Cancer Research -- aacrjournals.org/clincancerre...

Through longitudinal genomic profiling at GBM disease progression post trial therapy, we identified diverse genomic resistance mechanisms to such multi-agent targeted regimens that included MAPK to PI3K-mTOR pathway shift, acquired mismatch repair deficiency, and acquired MGMT gene amplification

Promising efficacy using this genomically-tailored precision medicine approach relative to a comparator cohort of patients with recurrent glioblastoma treated with standard-of-care approaches without experimental agents, although toxicity from the treatment regimens was a substantial limitation

Sponsored by the UCSF Glioblastoma Precision Medicine Program and led by the esteemed neuro-oncologist Dr. Jennifer Clarke, we tested 18 novel genomically-tailored multi-agent targeted therapy drug combinations in adults with recurrent glioblastoma. braintumorcenter.ucsf.edu/research/gli...

Proud to share the results from our phase 1 clinical trial testing a genomically-tailored multi-agent treatment regimen in 30 adults with recurrent glioblastoma published today in aacrjournals.org/clincancerres. @CCR_AACR @neurosurgucsf.bsky.social t.co/niMlNGjgQ5

Proud to share our new research lab website at
@stanfordbraintumor.bsky.social and #StanfordPathology:
med.stanford.edu/solomon-lab.html

final O'ahu sunset at #SNO2025 before returning back to @stanfordbraintumor.bsky.social to continue in our collaborative quest to cure brain tumors

So much exciting progress in the fight against #BrainTumors presented at this year's Society for Neuro-Oncology Annual Meeting #SNO2025. Thanks to all the incredible @neuroonc.bsky.social staff and colleagues around the world for putting this conference together! Looking forward to #SNO2026

Thanks to support from the Gilbert Family Foundation's Curing Neurofibromatosis program, we are now building the first single cell atlas of NF1-associated gliomas spanning the different molecular subtypes & also both pre- and post-treatment tumors #SNO2025
gilbertfamilyfoundation.org/curing-neuro...

Thanks to generous support from the Gilbert Family Foundation, Morgan Adams Foundation, Sandler Foundation, and Panattoni Family Foundation, we identified that gliomas arising in the setting of neurofibromatosis type 1 (NF1) are predominantly composed of three major molecular subtypes #BrainTumors

cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics Abstract. Genome-wide DNA methylation signatures correlate with and distinguish central nervous system (CNS) tumor types. Since the publication of the init

A new open access article: cIMPACT-NOW update 9 – recommendations on genome-wide DNA methylation profiling for CNS tumor diagnostics – is now available in Neuro Oncology Advances 🔗 academic.oup.com/noa/article/... 🔓 #EANOessentials #NeuroOncology #MalignantBrainTumor

UMAP plot of the 23 methylation classes of kidney tumors we identified associated with distinct histologic features, genetic alterations, and clinical outcomes. Can now be used as the roadmap for more accurate classification of future patient tumor samples. Strong work Antonios, Omkar, and team!

Fantastic multi-institutional collaboration with GU pathology colleagues at Stanford, UCSF, NIH, & NYU developing a DNA methylation-based classifier for human kidney tumors now in press at @modernpathology.bsky.social:
www.modernpathology.org/article/S089...

Great teamwork with Craig Horbinski and colleagues highlighting the necessity of molecular testing for the accurate diagnosis & treatment of #braintumor. Still championing for insurance approval of this testing in 2025 to ensure routine patient access @braintumor.org
jamanetwork.com/journals/jam...

It's an incredible honor to be embarking on the next phase of my physician-scientist career at @stanfordbraintumor.bsky.social & @stanfordmedicine.bsky.social with generous support from the NINDS/NIH, Gilbert Family Foundation, Ben and Catherine Ivy Foundation, and Morgan Adams Foundation

It's been an incredible first year since joining this amazing group at @stanfordbraintumor.bsky.social & @stanfordnsurg.bsky.social. Looking forward to many more years of pioneering research, excellent patient care, and educating the next-gen of physician-scientists at
@stanfordmedicine.bsky.social

Dr. Nadeem Al-Adli presenting on our group's groundbreaking glioblastoma research at #SNO2024 identifying distinct patterns of epigenomic evolution of these #braintumors following therapy compared to IDH-mutant astrocytomas

Dr. Calixto-Hope Lucas presenting on our group's groundbreaking glioblastoma research at #SNO2024

Remembering fun times at #SNO2024 and looking forward to #SNO2025 in Honolulu in just a few short weeks with @neuroonc.bsky.social and colleagues from @stanfordnsurg.bsky.social & around the globe